Exelixis | EXEL - Stammkapital

Aktienkurs
44.27
Täglich Wechseln
-1.14 -2.51%
Monatlich
6.04%
Jährlich
25.38%
Q2 Prognose
43.06




Stammkapital Veränderung Datum
Acadia Pharmaceuticals USD 169.18M 470K 2025-12
Agios Pharmaceuticals USD 58.45M 169K 2025-12
Akebia Therapeutics USD 265.42M 199K 2025-12
Amgen USD 539M 1000K 2025-12
AstraZeneca USD 1.55B 206K 2025-12
Bayer EUR 982.42M 0 2025-12
BioMarin Pharmaceutical USD 192.3M 201K 2025-12
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Cytokinetics USD 122.26M 145K 2025-12
Eisai JPY 282.11M 1000 2025-12
Eli Lilly USD 946.83M 354.23M 2025-06
Esperion Therapeutics USD 245.22M 39.79M 2025-12
Exelixis USD 268.1M 2.03M 2025-09
Genmab DKK 61.62M 52K 2025-12
Glaxosmithkline GBP 4.08B 49.43M 2025-12
Incyte USD 198.46M 2.33M 2025-12
Ionis Pharmaceuticals USD 161.97M 836K 2025-12
MacroGenics USD 63.32M 60K 2025-12
Merck USD 2.49B 15.79M 2025-09
Moderna USD 391M 2M 2025-09
Nektar Therapeutics USD 20.38M 20.36M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 10.64M 2025-12
Pfizer USD 5.69B 1000K 2025-09
Puma Biotechnology USD 5K 0 2024-06
Takeda JPY 1.58B 2K 2025-12
Ultragenyx Pharmaceutical USD 96.44M 88K 2025-09
Xencor USD 71.87M 529K 2025-12